Several interested parties in Japan
Regeneus has revised expected timing of an osteoarthritis (OA) clinical development licence deal for Progenza in Japan to Q4 CY18 (vs Q218); it is currently in active discussions with several parties. A licence deal would trigger a US$5m milestone payment from partner AGC and would effectively see Progenza commence a Phase II trial in knee OA in Japan.
Positive clinical trial results for cancer vaccine
Cancer vaccine trial meets primary endpoint of safety with promising signs of immune response
Key pointsRegeneus: leveraging the power of MSC`s
Article from CCRM
Regeneus works to improve people and animals’ lives through the application of proprietary stem cell and immuno-oncology technologies.
New hope for osteoarthritis sufferers
The Australian Financial Review
The company is excited about the potential for Progenza to address chronic pain relief ...
John Martin, Regeneus
Positive trial results of Progenza for knee osteoarthritis
Progenza granted Advanced Therapy Medicinal Product designation by European Medicines Agency